[Antipsychotic efficacy of neuroleptic neuropeptides in schizophrenia. Review of clinical data].
Recently much interest has been shown in the antipsychotic efficacy of neuroleptic-like neuropeptides in schizophrenia. In this article the clinical effects of the non-opioid fragments of gamma-endorphin, the so-called gamma-type endorphins DT gamma E and DE gamma E are reviewed. In addition, preliminary clinical studies of peptides related to cholecystokinin are considered. It is concluded that gamma-type endorphins possess antipsychotic properties in a subgroup of patients who may belong to Type I schizophrenia. With cholecystokinin-related peptides, in particular ceruletide, antipsychotic effects have been reported, which seem to be more or less comparable to those observed with gamma-type endorphins.
D014150:Antipsychotic Agents / Q000627:therapeutic use*; D002766:Cholecystokinin / Q000627:therapeutic use*; D004723:Endorphins / Q000627:therapeutic use*; D006801:Humans; D012559:Schizophrenia / Q000188:drug therapy*; D012562:Schizophrenia, Disorganized / Q000188:drug therapy; D012563:Schizophrenia, Paranoid / Q000188:drug therapy; D018823:gamma-Endorphin
D014150:Antipsychotic Agents; D004723:Endorphins; D018823:gamma-Endorphin; D002766:Cholecystokinin
Efficacité antipsychotique des neuropeptides neuroleptiques dans la schizophrénie. Revue des données cliniques.